Explanipedia

Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT Open

Rama Al Hamed, Myriam Labopin, Depei Wu, Tobias Gedde‐Dahl, Mahmoud Aljurf , et al. · 2024

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms? Open

Christof Scheid, Diderik-Jan Eikema, Michel van Gelder, Urpu Salmenniemi, Johan Maertens , et al. · 2024

In patients with myelodysplastic syndrome (MDS), higher revised International Prognostic Scoring System (IPSS-R) scores at transplant are associated with worse transplant outcome and, thus, lowering IPSS-R scores by therapeutic interventio…

Do Infectious Diseases After Kidney Retransplantation Differ From Those After First Kidney Transplantation? Open

Katharina Kusejko, Dionysios Neofytos, Christian van Delden, Hans H. Hirsch, Pascal Meylan , et al. · 2024

Background Infectious diseases (IDs) are highly relevant after solid organ transplantation in terms of morbidity and mortality, being among the most common causes of death. Patients undergoing kidney retransplantation (re-K-Tx) have been a…

Correction: Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan Open

Claire Seydoux, Chakradhara Rao S. Uppugunduri, Michael Medinger, Tiago Nava, Joerg Halter , et al. · 2023

Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT Open

Khalil Ben Hassine, Claire Seydoux, Sonia Khier, Youssef Daali, Michael Medinger , et al. · 2023

Therapeutic drug monitoring (TDM) of busulfan (Bu) is well-established in pediatric hematopoietic stem cell transplantation (HSCT), but its use in adults is limited due to a lack of clear recommendations and scarcity of evidence regarding …

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party Open

Olaf Penack, Christophe Peczynski, Christian Koenecke, Emmanuelle Polge, Robin Sanderson , et al. · 2023

We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blo…

P1282: MOCRAVIMOD IMPROVES OVERALL SURVIVAL IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Open

Michael Medinger, Jakob Passweg, Christoph Bucher, Jürgen Finke, Urs Schanz , et al. · 2023

Topic: 22. Stem cell transplantation - Clinical Background: Mocravimod (MOC) is a sphingosine-1-phosphate receptor (S1PR) modulator in pivotal stage clinical development for preventing relapse in acute myeloid leukemia (AML) patients (pts)…

Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm Open

Max J. Rieger, Sebastian M. Stolz, Antonia Müller, Rahel Schwotzer, Gayathri Nair , et al. · 2023

Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm Open

Max J. Rieger, Sebastian M. Stolz, Antonia Müller, rahel schwotzer, Gayathri Nair , et al. · 2023

Hematopoietic cell transplantation from haploidentical donors (haploHCT) has facilitated treatment of AML and MDS by increasing donor availability and became more feasible since the introduction of post-transplant cyclophosphamide (ptCY). …

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan Open

Claire Seydoux, Chakradhara Rao S. Uppugunduri, Michael Medinger, Tiago Nava, Joerg Halter , et al. · 2023

Busulfan (Bu) combined with cyclophosphamide (Cy) is commonly used as a myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT). There is inter-individual variability of Bu pharmacokinetics (PK) and …

Targeted Large-Volume Lymphocyte Removal Using Magnetic Nanoparticles in Blood Samples of Patients with Chronic Lymphocytic Leukemia: A Proof-of-Concept Study Open

Stefanie Janker, Simon Doswald, Roman R. Schimmer, Urs Schanz, Wendelin J. Stark , et al. · 2023

In the past, our research group was able to successfully remove circulating tumor cells with magnetic nanoparticles. While these cancer cells are typically present in low numbers, we hypothesized that magnetic nanoparticles, besides catchi…

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party Open

Olaf Penack, Christophe Peczynski, Christian Koenecke, Emmanuelle Polge, Andrea Kühnl , et al. · 2023

We investigated the incidence and outcome of anti-CD19 chimeric antigen receptor (CAR) T-cells-associated Common Terminology Criteria for Adverse Events (CTCAE) ≥grade 3 cytopenia. In the EBMT CAR-T registry, we identified 398 adult patien…

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020 Open

Helena Simeunovic, Martina Dickenmann, Mitja Nabergoj, Helen Baldomero, Stavroula Masouridi‐Levrat , et al. · 2022

Despite the high cure rate with initial therapy, approximately 10% of Hodgkin lymphoma (HL) patients are refractory to initial treatment, and up to 30% of patients will relapse after achieving initial complete remission. Despite promising …

Emberger Syndrome – A Family History Over 3 Generations Open

Laura Rüegsegger, Urs Schanz, Katja Seipel, Thomas Pabst, Jürg Schwegler , et al. · 2022

# Introduction Haploinsufficiency of _GATA2_ leads to impaired genesis and function of hematopoietic stem and progenitor cells, resulting in impairment of all subsequent blood cell lineages. Germline mutations in _GATA2_ are transmitted by…

Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation Open

Andriyana K. Bankova, Chloé Pasin, Alice Huang, Caroline Cicin‐Sain, Selina Epp , et al. · 2022

Summary Allogeneic haematopoietic cell transplantation (allo‐HCT) recipients show impaired antibody (Ab) response to a standard two‐dose vaccination against severe acute respiratory syndrome coronavirus‐2 and currently a third dose is reco…

Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys Open

Olaf Penack, Christophe Peczynski, Christian Koenecke, Emmanuelle Polge, Victoria Potter , et al. · 2022

The complete risk profile of CD19+ CAR T-cells could not been defined in the relatively small initial trials leading to approval of CAR T-cell products; and therefore authorities obliged CART-centers to report toxicity data on commercial C…

Allogeneic hematopoietic stem cell transplantation in non‐Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better Open

Ekaterina Rebmann, Mitja Nabergoj, Bastien Grandjean, Paraskevi Stakia, Alix Stern , et al. · 2022

Due to relatively high nonrelapse mortality (NRM), allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in non‐Hodgkin's lymphoma (NHL) remains the ultimate line of treatment but the only curable approach in a setting of relapse/…

Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates Open

Mihaela Sava, Veronika Bättig, Sabine Gerull, Jakob Passweg, Nina Khanna , et al. · 2022

B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Open

Valentin von Niederhäusern, Josefine Ruder, Marie Ghraichy, Ilijas Jelčić, Antonia Müller , et al. · 2022

Our detailed characterization of B-cell reconstitution after aHSCT in MS indicates a reduced reactivation potential of memory B cells up to 1 year after transplantation, which may leave patients susceptible to infection, but may also be an…

Surgical site infections after simultaneous pancreas kidney and pancreas transplantation in the Swiss Transplant Cohort Study Open

Peter W. Schreiber, Mirjam Laager, K. Boggian, Dionysios Neofytos, Christian van Delden , et al. · 2022

Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study Open

Maja Weisser, Mihaela Sava, Veronika Baettig, Sabine Gerull, Jakob Passweg , et al. · 2022

Empiric antibiotic treatment for bloodstream infection (BSI) after haematopoietic cell transplantation (HCT) in the era of antimicrobial resistance is challenging. We conducted a nested project in the Swiss Transplant Cohort Study 09/2009 …

S235: A TWO-PART, SINGLE- AND TWO-ARM RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE S1P RECEPTOR MODULATOR KRP203 IN SUBJECTS WITH HEMATOLOGICAL MALIGNANCIES Open

S. dertschnig, Jürgen Finke, Dominik Heim, Urs Schanz, Ernst Holler , et al. · 2022

Background: The success of allogeneic hematopoietic stem cell transplantation (HSCT) is limited by disease relapse. Alloreactive donor T cells have the potential to prevent relapse by the graft-versus-leukemia (GVL) response. The GVL respo…

P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION Open

Grzegorz Basak, Christophe Peczynski, Christian Koenecke, Sofie Terwel, Y. Cabrerizo , et al. · 2022

Background: CAR T-cell therapies have been associated with a profile of significant toxicities and previously unknown side effects. For that reason, the registration of clinical trials with commercial and non-commercial products included v…

Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10 years Open

Kevin Hofer, Urs Schanz, Rahel Schwotzer, Gayathri Nair, Markus G. Manz , et al. · 2022

Successful Induction of Specific Immunological Tolerance by Combined Kidney and Hematopoietic Stem Cell Transplantation in HLA-Identical Siblings Open

Thomas Fehr, Kerstin Hübel, Olivier de Rougemont, Irène A. Abela, Ariana Gaspert , et al. · 2022

Induction of immunological tolerance has been the holy grail of transplantation immunology for decades. The only successful approach to achieve it in patients has been a combined kidney and hematopoietic stem cell transplantation from an H…

Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation Open

Alice Huang, Caroline Cicin‐Sain, Chloé Pasin, Selina Epp, Annette Audigé , et al. · 2022

Vaccines against SARS-CoV-2 have been rapidly approved. Although pivotal studies were conducted in healthy volunteers, little information is available on the safety and efficacy of mRNA vaccines in immunocompromised patients, including rec…

NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Open

Josefine Ruder, Jordan Rex, Simon Obahor, María José Docampo, Antonia Müller , et al. · 2021

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, in which autoreactive T and B cells play important roles. Other lymphocytes such as NK cells and innate-like T cells appear to be involved as well. To name a f…

Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation Open

Caroline Cicin‐Sain, Alice Huang, Chloé Pasin, Selina Epp, Nicolas J. Mueller , et al. · 2021

Background: Vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved rapidly. However, pivotal studies have been conducted in healthy volunteers, while recipients of allogeneic hematopoietic cell…

Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey Open

Leopold Sellner, Johannes Schetelig, Linda Köster, Goda Choi, Didier Blaise , et al. · 2021

Pre‐transplant donor‐specific HLA antibodies and risk for poor first‐year renal transplant outcomes: results from the Swiss Transplant Cohort Study Open

Caroline Wehmeier, Patrizia Amico, Daniel Sidler, Urs Wirthmüller, Karine Hadaya , et al. · 2021

The aim of this study was to analyze first year renal outcomes in a nationwide prospective multicenter cohort comprising 2215 renal transplants, with a special emphasis on the presence of pre-transplant donor-specific HLA antibodies (DSA).…

Urs Schanz YOU? Author Swipe